Rodger Novak's Insider Trades & SAST Disclosures
Rodger Novak's most recent trade in CRISPR Therapeutics AG was a trade of 25,000 Common Shares done at an average price of $165 . Disclosure was reported to the exchange on June 30, 2021.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Rodger Novak.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Sale of securities on an exchange or to another person at price $ 165.00 per share. | 30 Jun 2021 | 25,000 | 573,007 (0%) | 0% | 165 | 4,125,000 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Sale of securities on an exchange or to another person at price $ 156.55 per share. | 28 Jun 2021 | 25,000 | 598,007 (0%) | 0% | 156.6 | 3,913,750 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Sale of securities on an exchange or to another person at price $ 128.76 per share. | 21 Jun 2021 | 12,630 | 630,356 (1%) | 0% | 128.8 | 1,626,239 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Sale of securities on an exchange or to another person at price $ 129.46 per share. | 21 Jun 2021 | 7,299 | 623,057 (1%) | 0% | 129.5 | 944,929 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Sale of securities on an exchange or to another person at price $ 127.71 per share. | 21 Jun 2021 | 2,969 | 642,986 (1%) | 0% | 127.7 | 379,171 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Sale of securities on an exchange or to another person at price $ 125.58 per share. | 21 Jun 2021 | 1,171 | 646,836 (1%) | 0% | 125.6 | 147,054 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Sale of securities on an exchange or to another person at price $ 126.62 per share. | 21 Jun 2021 | 881 | 645,955 (1%) | 0% | 126.6 | 111,552 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Sale of securities on an exchange or to another person at price $ 130.28 per share. | 21 Jun 2021 | 50 | 623,007 (1%) | 0% | 130.3 | 6,514 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Sale of securities on an exchange or to another person at price $ 125.00 per share. | 30 Nov 2020 | 50,000 | 648,007 (1%) | 0% | 125 | 6,250,000 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.43 per share. | 30 Nov 2020 | 50,000 | 698,007 (1%) | 0% | 14.4 | 721,500 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2020 | 50,000 | 61,893 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.00 per share. | 30 Nov 2020 | 50,000 | 698,007 (1%) | 0% | 14 | 700,000 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2020 | 50,000 | 140,315 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Sale of securities on an exchange or to another person at price $ 125.00 per share. | 30 Nov 2020 | 50,000 | 648,007 (1%) | 0% | 125 | 6,250,000 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Sale of securities on an exchange or to another person at price $ 100.00 per share. | 08 Oct 2020 | 22,238 | 648,007 (1%) | 0% | 100 | 2,223,800 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2020 | 22,238 | 193,077 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.43 per share. | 08 Oct 2020 | 22,238 | 670,245 (1%) | 0% | 14.4 | 320,894 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2020 | 2,762 | 190,315 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Sale of securities on an exchange or to another person at price $ 100.00 per share. | 08 Oct 2020 | 2,762 | 648,007 (1%) | 0% | 100 | 276,200 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.43 per share. | 08 Oct 2020 | 2,762 | 650,769 (1%) | 0% | 14.4 | 39,856 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.43 per share. | 01 Sep 2020 | 21,067 | 673,007 (1%) | 0% | 14.4 | 303,997 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2020 | 21,067 | 215,315 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Sale of securities on an exchange or to another person at price $ 92.59 per share. | 01 Sep 2020 | 19,754 | 651,847 (1%) | 0% | 92.6 | 1,829,023 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.00 per share. | 01 Sep 2020 | 3,933 | 651,940 (1%) | 0% | 14 | 55,062 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2020 | 3,933 | 111,893 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Sale of securities on an exchange or to another person at price $ 93.19 per share. | 01 Sep 2020 | 3,840 | 648,007 (1%) | 0% | 93.2 | 357,850 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Sale of securities on an exchange or to another person at price $ 91.54 per share. | 01 Sep 2020 | 1,406 | 671,601 (1%) | 0% | 91.5 | 128,705 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Sale of securities on an exchange or to another person at price $ 100.00 per share. | 19 Aug 2020 | 25,000 | 648,007 (1%) | 0% | 100 | 2,500,000 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2020 | 25,000 | 115,826 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.00 per share. | 19 Aug 2020 | 25,000 | 673,007 (1%) | 0% | 14 | 350,000 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Sale of securities on an exchange or to another person at price $ 90.00 per share. | 07 Jul 2020 | 25,000 | 648,007 (1%) | 0% | 90 | 2,250,000 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.00 per share. | 07 Jul 2020 | 19,414 | 673,007 (1%) | 0% | 14 | 271,796 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2020 | 19,414 | 140,826 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.81 per share. | 07 Jul 2020 | 5,586 | 653,593 (1%) | 0% | 1.8 | 10,111 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2020 | 5,586 | 0 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Sale of securities on an exchange or to another person at price $ 80.00 per share. | 01 Jul 2020 | 50,000 | 648,007 (1%) | 0% | 80 | 4,000,000 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Sale of securities on an exchange or to another person at price $ 75.00 per share. | 23 Jun 2020 | 50,000 | 698,007 (1%) | 0% | 75 | 3,750,000 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Sale of securities on an exchange or to another person at price $ 70.27 per share. | 22 May 2020 | 36,616 | 748,007 (1%) | 0% | 70.3 | 2,573,006 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Sale of securities on an exchange or to another person at price $ 70.01 per share. | 22 May 2020 | 13,384 | 784,623 (1%) | 0% | 70.0 | 937,014 | Common Shares |
| CRISPR Therapeutics AG | Rodger Novak | Director, President | Sale of securities on an exchange or to another person at price $ 65.00 per share. | 19 May 2020 | 50,000 | 798,007 (1%) | 0% | 65 | 3,250,000 | Common Shares |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges